Apex BiotechnologyTPE:1733 +1.34%82 Current Ratio is 3.87 as of Dec. 2025, which is 28% above its 10-year median of 3.03. GuruFocus rates TPE:1733 with a GF Score™ of 82/100 and a GF Value™ of NT$30.08 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,409 Biotechnology companies, Apex Biotechnology ranks worse than 50.32% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Apex Biotechnology's current ratio for the quarter that ended in Dec. 2025 was 3.87.
Apex Biotechnology has a current ratio of 3.87. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Apex Biotechnology's Current Ratio or its related term are showing as below:
TPE:1733'
s Current Ratio Range Over the Past 10 Years
Min: 1.57 Med: 3.03 Max: 3.93
Current: 3.87
During the past 13 years, Apex Biotechnology's highest Current Ratio was 3.93. The lowest was 1.57. And the median was 3.03.
TPE:1733's Current Ratio is ranked worse than 50.32% of 1409
companies
in the Biotechnology industry
Industry Median: 3.89
vs TPE:1733: 3.87
Apex Biotechnology (TPE:1733) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Apex Biotechnology Current Ratio Related Terms
Apex Biotechnology Current Ratio Historical Data
* Premium members only.
The historical data trend for Apex Biotechnology's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1733 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Apex Biotechnology's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apex Biotechnology Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apex Biotechnology's Current Ratio distribution charts can be found below:
* The bar in red indicates where Apex Biotechnology's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apex Biotechnology (TPE:1733) has a Current Ratio of 3.87 as of Dec. 2025. This is 28% above median its historical median of 3.03. Over the past decade, Apex Biotechnology's Current Ratio has ranged from 1.57 to 3.93. According to the industry distribution chart, Apex Biotechnology ranks #709 out of 1409 companies in the Biotechnology industry, placing it in the top 50.3%.
Is Apex Biotechnology's Current Ratio too high?
Apex Biotechnology's current Current Ratio of 3.87 is 28% above median its 10-year median of 3.03. Over the past 10 years, this metric has ranged from a low of 1.57 to a high of 3.93. The Biotechnology industry median Current Ratio is 3.89. Apex Biotechnology's value of 3.87 is 0.5% below this industry median. Based on the distribution chart, Apex Biotechnology ranks #709 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Apex Biotechnology has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Apex Biotechnology ranks #709 out of 1409 companies for Current Ratio. This places Apex Biotechnology in the lower half of its industry. The industry median Current Ratio is 3.89. Apex Biotechnology's value of 3.87 is 0.5% below this benchmark. Historically, Apex Biotechnology's own Current Ratio has ranged from 1.57 to 3.93 over the past decade. While the company's 10-year median is 3.03 vs. the industry median of 3.89, Apex Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apex Biotechnology's current Current Ratio of 3.87 is 0.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apex Biotechnology's current Current Ratio is 3.87, which is 28% above median its own 10-year median of 3.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$30.08, compared to a current price of NT$30.30 — trading 0.7% above its estimated fair value. The current Current Ratio is 3.87, which is 28% above median its 10-year median of 3.03 and 0.5% below the Biotechnology industry median of 3.89. Apex Biotechnology's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current Current Ratio is 3.87 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apex Biotechnology (TPE:1733) Overvalued in 2026?
Based on GuruFocus' analysis, Apex Biotechnology stock appears to be overvalued.
The current stock price of NT$30.30 is trading 0.7% above its estimated GF Value™ of NT$30.08.
GuruFocus considers Apex Biotechnology to be Fairly Valued.
Key valuation signals for TPE:1733:
Current Ratio: 3.87 (28% above median its 10-year median of 3.03)
GF Value™: NT$30.08 vs. price of NT$30.30 (0.7% above fair value)
Industry Position: 0.5% below the Biotechnology median (#709 of 1409)
No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
82GF Score
Get the complete analysis for TPE:1733
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1733 has been successfully added to your 
